Found 383 Results - Page 4 of 39
B Cell (IGH) Gene Rearrangement
PCR of IgH framework regions to detect clonal IgH gene rearrangements by 1, 2, 3 and joining regions. It locates clonal B-cell immunoglobulin gene rearrangements.
B Cell (IGK) Gene Rearrangement
Specific oligonucleotides that recognize the Vk, intragenic and Jk regions are used to perform Ig Kappa gene rearrangement analysis. It identifies monoclonal B-cell immunoglobulin gene rearrangement.
[ t(9;22)/BCR-ABL1, KMT2A(MLL)-Breakapart, t(12;21)/ETV6-RUNX1, CRLF2-Breakapart, CEP4/CEP10/CEP17]
*IF NEGATIVE, REFLEX TO: [9p21/CDKN2A-CEP9, IGH- Breakapart, MYC-Breakapart]
*IF gain of ETV6, REFLEX TO: [ETV6-Breakapart]
B72.3 (TAG72)
The monoclonal antibody (B72.3) to tumor-associated glycoprotein identifies a neoplasm-associated oncofetal antigen (TAG-72) expressed by numerous human adenocarcinomas, including by most invasive ductal breast, colonic, pancreatic, gastric, esophageal, lung, ovarian and endometrial adenocarcinomas. This antigen is also expressed on normal secretory endometrium, but not on other normal tissues.
BCL-1 (Cyclin D1)
BCL1/Cyclin D1 is a nuclear protein detectable in formalin-fixed, paraffin-embedded (FFPE) sections. It is found in the majority of mantle cell lymphomas. Hairy cell leukemia and plasmacytoma may also express BCL1 with a weaker signal. BCL1 is an oncogene acting as a cell cycle regulator. 
B-cell lymphoma 2 (BCL2) is a translocation-associated protein identified in lymphomas and a wide range of other neoplasms. Most cases of follicular lymphoma have a [t(14;18)] translocation, resulting in BCL2 overexpression. Overexpression of BCL2 in activated diffuse B-cell lymphoma may predict disease progression.
BCL-2 t(14;18) Translocation Assay
Test uses PCR and fragment analysis for quantitative detection of IGH-BCL2 translocations, which are associated with 70-80% of follicular lymphoma and approximately 20% of diffuse large B-cell lymphoma. Identifies translocations involving the major (MBR), minor (MCR), and 3' MBR sub-cluster regions of BCL2. Positive results quantify the ratio of mutant BCL2 to internal control DNA. this test is useful to confirm the diagnosis of follicular lymphoma, monitor effectiveness of treatment, and to detect minimal residual disease or recurrence.
The BCL6 antibody stains the follicular cells and interfollicular cells in follicular lymphoma, germinal center cells in lymphoid follicles, some types of diffuse large B-cell lymphomas, Burkitt lymphoma, and the majority of Reed-Sternberg cells in nodular lymphocyte predominant Hodgkin lymphoma. Conversely, BCL6 rarely stains mantle cell lymphoma and MALT lymphoma. While BCL6 expression is seen in approximately half of CD30+ anaplastic large cell lymphomas, it is absent in other peripheral T-cell lymphomas.